News

Very high tumor burden is a potential biomarker that may predict response to anti–PD-L1 therapy in patients of Asian descent across cancer types.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.

Karim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.

Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.

ADX-2191 will not be granted approval by the FDA due to the results of the phase 3 GUARD trial.

Druggable targets for patients with gastrointestinal cancers were discussed during the 20th Annual Meeting of the International Society of Gastrointestinal Oncology.

The phase 1 study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-253 monotherapy in patients with acute myeloid leukemias.

Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

Benjamin Besse, MD, PhD, discusses the main findings and next steps of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated non–small cell lung cancer.

Additional data have led to a full FDA approval for blinatumomab.

VEGFR inhibitors, mTOR inhibitors, and immune checkpoint inhibitors have been studied as adjuvant therapy for patients with RCC. However, conflicting data from phase 3 trials have left investigators unclear on what their role is.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Two brentuximab vedotin/chemotherapy regimens demonstrated similar efficacy, but varied in terms of safety and preservation of fertility, according to an ICML presentation.

Following positive data from the phase 3 IMerge study of imetelstat, the FDA has received a new drug submission for the agent for the treatment of patients with relapsed or refractory myelodysplastic syndrome.

The safety and efficacy of the combination of lifileucel and pembrolizumab is being assessed in the phase 3 TILVANCE-301 among patients with untreated, unresectable, or metastatic melanoma.

Combining sintilimab and axitinib led to tumor shrinkage and a tolerable safety profile in patients with advanced FH-deficient renal cell carcinoma.

On the heels of an ASCO presentation of data from the phase 3 TALAPRO-2 trial, the FDA has granted approval to the study combination for the treatment of a metastatic castration-resistant prostate cancer subgroup.

According to phase 3 study results, the combination of pembrolizumab and chemotherapy can induce high rates of response in patients with gastroesophageal junction adenocarcinoma while maintaining safety.

Although dosing will continue in iMMagine-1 for patients who responded well to CART-ddBCMA, recruitment has been halted due to to a safety concern.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

A time-based pathway to final analysis has been cleared by the FDA to evaluate the effect of uproleselan on relapsed/refractory acute myeloid leukemia.

Following a report of a serious grade 5 adverse event, the phase 1 PLAT-08 trial of SC-DARIC33 in pediatric patients with acute myeloid leukemia has been placed on hold

Data from a phase 1 dose escalation study showed tolerability and antitumor activity with IBI351 in patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.

Samer A. Srour, MD, discusses research on Orca-Q for patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

Results from 2 trials of lisocabtagene maraleucel presented at ICML 2023 demonstrated efficacy and tolerability in patients with follicular lymphoma and mantle cell lymphoma.

Individual data from 2 studies evaluating rezivertinib in patients with advanced non–small cell lung cancer harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.

mRNA-4157/V940 in combination with pembrolizumab improved recurrence-free survival in patients with high-risk melanoma.

Pemigatinib showed antitumor activity in patients with cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.